{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:21:34Z","timestamp":1787937694765,"version":"build-2784847793"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01719-w","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:58:37Z","timestamp":1787893117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Safety in the Era of Artificial Intelligence: Promises, Limits, and the Case for an Enterprise Lifecycle Evidence Ecosystem"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-4716","authenticated-orcid":false,"given":"Tarek A.","family":"Hammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Rochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Gofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-3653","authenticated-orcid":false,"given":"Andrew","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"2","key":"1719_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s43441-025-00899-4","volume":"60","author":"K Getz","year":"2026","unstructured":"Getz K, Botto E, Calduch Arques A, Galuchie L, Camargo Sanmiguel N, Sheetz N, et al. Insights informing strategies for optimizing the collection of clinical trial data. Ther Innov Regul Sci. 2026;60(2):563\u201374. https:\/\/doi.org\/10.1007\/s43441-025-00899-4.","journal-title":"Ther Innov Regul Sci"},{"issue":"31","key":"1719_CR2","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/JCO.21.01210.","journal-title":"J Clin Oncol"},{"key":"1719_CR3","doi-asserted-by":"publisher","first-page":"1193413","DOI":"10.3389\/fdsfr.2023.1193413","volume":"3","author":"TA Hammad","year":"2023","unstructured":"Hammad TA, Afsar S, McAvoy LB, Le Louet H. Aspects to consider in causality assessment of safety signals: broadening the thought process. Front Drug Saf Regul. 2023;3:1193413. https:\/\/doi.org\/10.3389\/fdsfr.2023.1193413.","journal-title":"Front. Drug. Saf. Regul."},{"key":"1719_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2021.106398.PMID:34756484;PMCID:PMC8806333","volume":"165","author":"M Sprajcer","year":"2022","unstructured":"Sprajcer M, Thomas MJW, Sargent C, Crowther ME, Boivin DB, Wong IS, et al. How effective are fatigue risk management systems? A review Accid Anal Prev. 2022;165:106398. https:\/\/doi.org\/10.1016\/j.aap.2021.106398.PMID:34756484;PMCID:PMC8806333.","journal-title":"A review. Accid Anal Prev."},{"key":"1719_CR5","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module IX, Signal management. Rev 1. Amsterdam: EMA; 2017. [Internet, cited 2026 August 20] Available from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf."},{"key":"1719_CR6","volume-title":"Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII","author":"Council for International Organizations of Medical Sciences","year":"2010","unstructured":"Council for International Organizations of Medical Sciences. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Geneva: CIOMS; 2010."},{"key":"1719_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-026-01700-7","author":"TA Hammad","year":"2026","unstructured":"Hammad TA, Rochon J, Afsar S, Lee SH, Ely DM, Hassanpour N, et al. Augmenting medical judgment in signal confirmation: design considerations for an AI-enabled causality assessment framework. Drug Saf. 2026. https:\/\/doi.org\/10.1007\/s40264-026-01700-7.","journal-title":"Drug Saf"},{"key":"1719_CR8","doi-asserted-by":"publisher","unstructured":"Collins GS, Dhiman P, Andaur Navarro CL, Ma J, Hooft L, Reitsma JB, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378. Available at: https:\/\/www.bmj.com\/content\/385\/bmj-2023-078378.","DOI":"10.1136\/bmj-2023-078378"},{"key":"1719_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","volume":"388","author":"KGM Moons","year":"2025","unstructured":"Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505. https:\/\/doi.org\/10.1136\/bmj-2024-082505.","journal-title":"BMJ"},{"key":"1719_CR10","unstructured":"Fazal K, Thiagarajan S, Pandya V, Liu L. How predictive safety can help patients. Pharmaphorum. 2023 Apr 17. [Internet, cited 2026 August 20] Available from: https:\/\/pharmaphorum.com\/rd\/how-predictive-safety-can-help-patients."},{"issue":"2","key":"1719_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41573-025-01308-z","volume":"25","author":"CE Goldring","year":"2026","unstructured":"Goldring CE, Russomanno G, Pin C, Trairatphisan P, Beattie KA, Fisher CP, et al. Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety. Nat Rev Drug Discov. 2026;25(2):138\u201353. https:\/\/doi.org\/10.1038\/s41573-025-01308-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1719_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/clpt.2008.270","volume":"85","author":"WB Mattes","year":"2009","unstructured":"Mattes WB, Walker EG. Translational toxicology and the work of the Predictive Safety Testing Consortium. Clin Pharmacol Ther. 2009;85(3):327\u201330. https:\/\/doi.org\/10.1038\/clpt.2008.270.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1719_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18063\/JMDS.2015.01.007","volume":"1","author":"J-M Sauer","year":"2015","unstructured":"Sauer J-M, Walker EG, Porter AC. The Predictive Safety Testing Consortium: safety biomarkers, collaboration, and qualification. J Med Dev Sci. 2015;1(1):34\u201345. https:\/\/doi.org\/10.18063\/JMDS.2015.01.007.","journal-title":"J Med Dev Sci"},{"key":"1719_CR14","unstructured":"Critical Path Institute. Predictive Safety Testing Consortium [Internet]. Tucson (AZ): Critical Path Institute; 2024 Jan 23 [Internet, cited 2026 August 20]. Available from: https:\/\/c-path.org\/program\/predictive-safety-testing-consortium\/."},{"issue":"4","key":"1719_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/cpt.1362","volume":"105","author":"JP Menetski","year":"2019","unstructured":"Menetski JP, Hoffmann SC, Cush SS, Kamphaus TN, Austin CP, Herrling PL, et al. The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction. Clin Pharmacol Ther. 2019;105(4):829\u201343. https:\/\/doi.org\/10.1002\/cpt.1362.","journal-title":"Clin Pharmacol Ther"},{"key":"1719_CR16","unstructured":"Foundation for the National Institutes of Health. FNIH Biomarkers Consortium and Critical Path Institute achieve the first ever qualification of a clinical safety biomarker by the U.S. Food and Drug Administration [Internet]. North Bethesda (MD): FNIH; 2018 Oct 25 [Internet, cited 2026 August 20]. Available from: https:\/\/fnih.org\/press-release\/fnih-biomarkers-consortium-and-critical-path-institute-achieve-the-first-ever-qualification-of-a-clinical-safety-biomarker-by-the-u-s-food-and-drug-administration\/."},{"key":"1719_CR17","unstructured":"U.S. Food and Drug Administration. Qualification Determination: DDTBMQ000014. Biomarker panel interpreted via a composite measure of urinary CLU, CysC, KIM-1, NAG, NGAL, and OPN for detection of kidney tubular injury in phase 1 trials. Silver Spring (MD): FDA; 2018 Jul 25. [Internet, cited 2026 August 20] Available from: https:\/\/www.fda.gov\/media\/115635\/download."},{"key":"#cr-split#-1719_CR18.1","unstructured":"U.S. Food and Drug Administration. Biomarker Letter of Support [Internet]. Silver Spring (MD): FDA August 2024"},{"key":"#cr-split#-1719_CR18.2","unstructured":"[Internet, cited 2026 August 20]. Available from: https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/letter-support-los#FDA_issued_Letters_of_Support."},{"issue":"1","key":"1719_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cpt.896","volume":"103","author":"J Vicente","year":"2018","unstructured":"Vicente J, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, et al. Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the \u201cCiPA\u201d initiative and design of a prospective clinical validation study. Clin Pharmacol Ther. 2018;103(1):54\u201366. https:\/\/doi.org\/10.1002\/cpt.896.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1719_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004628","volume":"10","author":"Z Li","year":"2017","unstructured":"Li Z, Dutta S, Sheng J, Tran PN, Wu W, Chang K, et al. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-\u00e0-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology. Circ Arrhythm Electrophysiol. 2017;10(2):e004628. https:\/\/doi.org\/10.1161\/CIRCEP.116.004628. (Erratum in: Circ Arrhythm Electrophysiol. 2017 Mar;10(3): e000024. 10.1161\/HAE.0000000000000024. PMID: 28202629).","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1719_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.767621","volume":"12","author":"T Matsui","year":"2021","unstructured":"Matsui T, Shinozawa T. Human organoids for predictive toxicology research and drug development. Front Genet. 2021;12:767621. https:\/\/doi.org\/10.3389\/fgene.2021.767621.","journal-title":"Front Genet"},{"key":"1719_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","volume":"2","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, et al. Organoids. Nat Rev Methods Primers. 2022;2:94. https:\/\/doi.org\/10.1038\/s43586-022-00174-y.","journal-title":"Nat Rev Methods Primers."},{"issue":"5","key":"1719_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","volume":"20","author":"LA Low","year":"2021","unstructured":"Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345\u201361. https:\/\/doi.org\/10.1038\/s41573-020-0079-3.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1719_CR24","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/CM9.0000000000004067","volume":"139","author":"H Li","year":"2026","unstructured":"Li H, Pan Y, Zheng Z, Lin R, Pan Y, Lin L, et al. Organoid models: regulations and prospects for the development of investigational new drugs. Chin Med J. 2026;139(9):1303\u201316. https:\/\/doi.org\/10.1097\/CM9.0000000000004067.","journal-title":"Chin Med J"},{"issue":"9","key":"1719_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.amjmed.2023.03.033","volume":"136","author":"EY Adashi","year":"2023","unstructured":"Adashi EY, O\u2019Mahony DP, Cohen IG. The FDA Modernization Act 2.0: drug testing in animals is rendered optional. Am J Med. 2023;136(9):853\u20134. https:\/\/doi.org\/10.1016\/j.amjmed.2023.03.033.","journal-title":"Am J Med"},{"issue":"6","key":"1719_CR26","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s12325-024-02870-5","volume":"41","author":"R De Abreu Ferreira","year":"2024","unstructured":"De Abreu Ferreira R, Zhong S, Moureaud C, Le MT, Rothstein A, Li X, et al. A pilot, predictive surveillance model in pharmacovigilance using machine learning approaches. Adv Ther. 2024;41(6):2435\u201345. https:\/\/doi.org\/10.1007\/s12325-024-02870-5.","journal-title":"Adv Ther"},{"key":"1719_CR27","unstructured":"U.S. Food and Drug Administration. M15 General Principles for Model-Informed Drug Development. Guidance for industry. Docket No. FDA-2024-D-5580. Fed Regist. 2026 Jun 3;91:33179-33181. [Internet, cited 2026 August 20] Available from: https:\/\/www.federalregister.gov\/documents\/2026\/06\/03\/2026-11112\/m15-general-principles-for-model-informed-drug-development-international-council-for-harmonisation."},{"key":"1719_CR28","unstructured":"European Medicines Agency. ICH M15 guideline on general principles for model-informed drug development. Step 5. EMA\/CHMP\/ICH\/496426\/2024. Amsterdam: European Medicines Agency; 2026 Feb 9. [Internet, cited 2026 August 20] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m15-guideline-general-principles-model-informed-drug-development-step-5_en.pdf."},{"key":"1719_CR29","unstructured":"U.S. Food and Drug Administration. General considerations for the use of new approach methodologies in drug development. Draft guidance for industry [Internet]. Silver Spring (MD): FDA; 2026 Mar [Internet, cited 2026 August 20]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-considerations-use-new-approach-methodologies-drug-development."},{"key":"1719_CR30","unstructured":"U.S. Food and Drug Administration. Guiding principles of good AI practice in drug development [Internet]. Silver Spring (MD): FDA; 2026 [Internet, cited 2026 August 20]. Available from: https:\/\/www.fda.gov\/about-fda\/artificial-intelligence-drug-development\/guiding-principles-good-ai-practice-drug-development."},{"key":"1719_CR31","unstructured":"European Medicines Agency. EMA and FDA set common principles for AI in medicine development [Internet]. Amsterdam: EMA; 2026 Jan 14 [Internet, cited 2026 August 20]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-fda-set-common-principles-ai-medicine-development-0."},{"key":"1719_CR32","unstructured":"Artificial Intelligence in Pharmacovigilance.  CIOMS Working Group XIV Report. Geneva, Switzerland: Council for International Organizations of Medical Sciences."},{"key":"1719_CR33","unstructured":"Innovative Health Initiative Call 11, Topic 3. Brussels: Innovative Health Initiative; 2025 [Internet, cited 2026 August 20]. Available from: https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/portal\/screen\/opportunities\/topic-details\/HORIZON-JU-IHI-2025-11-03-two-stage."},{"issue":"5","key":"1719_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s44360-025-00048-z","volume":"1","author":"L Tikhomirov","year":"2026","unstructured":"Tikhomirov L, Semmler C, Prizant N, Bhasin S, Kenyon G, van der Vegt A, et al. A scoping review of silent trials for medical artificial intelligence. Nat Health. 2026;1(5):532\u201354. https:\/\/doi.org\/10.1038\/s44360-025-00048-z.","journal-title":"Nat Health"},{"issue":"34","key":"1719_CR35","doi-asserted-by":"publisher","first-page":"E1351","DOI":"10.1503\/cmaj.202434","volume":"193","author":"AA Verma","year":"2021","unstructured":"Verma AA, Murray J, Greiner R, Cohen JP, Shojania KG, Ghassemi M, et al. Implementing machine learning in medicine. CMAJ. 2021;193(34):E1351\u20137. https:\/\/doi.org\/10.1503\/cmaj.202434.","journal-title":"CMAJ"},{"issue":"36","key":"1719_CR36","doi-asserted-by":"publisher","first-page":"E1425","DOI":"10.1503\/cmaj.210036","volume":"193","author":"T Antoniou","year":"2021","unstructured":"Antoniou T, Mamdani M. Evaluation of machine learning solutions in medicine. CMAJ. 2021;193(36):E1425\u20139. https:\/\/doi.org\/10.1503\/cmaj.210036.","journal-title":"CMAJ"},{"key":"1719_CR37","doi-asserted-by":"publisher","unstructured":"- Fang K, Powell G, Painter J, Bate A, Li M. The right amount of wrong: error injection for AI oversight. SSRN. 2026. Preprint. https:\/\/doi.org\/10.2139\/ssrn.7108438.","DOI":"10.2139\/ssrn.7108438"},{"issue":"3","key":"1719_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/0018720810376055","volume":"52","author":"R Parasuraman","year":"2010","unstructured":"Parasuraman R, Manzey DH. Complacency and bias in human use of automation: an attentional integration. Hum Factors. 2010;52(3):381\u2013410. https:\/\/doi.org\/10.1177\/0018720810376055.","journal-title":"Hum Factors"},{"issue":"1","key":"1719_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00146-025-02422-7","volume":"41","author":"G Romeo","year":"2026","unstructured":"Romeo G, Conti D. Exploring automation bias in human-AI collaboration: a review and implications for explainable AI. AI Soc. 2026;41(1):259\u201378. https:\/\/doi.org\/10.1007\/s00146-025-02422-7.","journal-title":"AI Soc"},{"key":"1719_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2495\/SAFE050411","volume":"82","author":"F Hofer","year":"2005","unstructured":"Hofer F, Schwaninger A. Using threat image projection data for assessing individual screener performance. WIT Trans Built Environ. 2005;82:417\u201326. https:\/\/doi.org\/10.2495\/SAFE050411.","journal-title":"WIT Trans Built Environ."},{"key":"1719_CR41","unstructured":"- van der Schaar M. Clinical trials as continuously learning systems: a multi-agent machine learning framework for end-to-end derisking of clinical trials using digital twins [Internet]. Version 4.0. Cambridge: van der Schaar Lab; 2026 Feb 12 [Internet, cited 2026 August 20]. Available from: https:\/\/www.vanderschaar-lab.com\/clinical-trials-as-continuously-learning-systems\/."},{"key":"1719_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01640-8","author":"A Youssef","year":"2025","unstructured":"Youssef A, Hammad TA. Pharmacovigilance due diligence in drug development: a practical playbook for risk identification, compliance assessment, and strategic decision making. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-025-01640-8.","journal-title":"Drug Saf"},{"key":"1719_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4939-7172-5_12","volume":"1641","author":"RJ Brennan","year":"2017","unstructured":"Brennan RJ. Target safety assessment: strategies and resources. Methods Mol Biol. 2017;1641:213\u201328. https:\/\/doi.org\/10.1007\/978-1-4939-7172-5_12.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1719_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0300985813505117","volume":"51","author":"VG Sasseville","year":"2014","unstructured":"Sasseville VG, Mansfield KG, Brees DJ. Safety biomarkers in preclinical development: translational potential. Vet Pathol. 2014;51(1):281\u201391. https:\/\/doi.org\/10.1177\/0300985813505117.","journal-title":"Vet Pathol"},{"issue":"7","key":"1719_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41573-024-00942-3","volume":"23","author":"RJ Brennan","year":"2024","unstructured":"Brennan RJ, Jenkinson S, Brown AR, et al. The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nat Rev Drug Discov. 2024;23(7):525\u201345. https:\/\/doi.org\/10.1038\/s41573-024-00942-3.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1719_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41573-022-00633-x","volume":"22","author":"F Pognan","year":"2023","unstructured":"Pognan F, Beilmann M, Boonen HCM, et al. The evolving role of investigative toxicology in the pharmaceutical industry. Nat Rev Drug Discov. 2023;22(4):317\u201335. https:\/\/doi.org\/10.1038\/s41573-022-00633-x.","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"1719_CR47","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1177\/15353702211002153","volume":"246","author":"JM Sauer","year":"2021","unstructured":"Sauer JM, Porter AC. Qualification of translational safety biomarkers. Exp Biol Med (Maywood). 2021;246(22):2391\u20138. https:\/\/doi.org\/10.1177\/15353702211002153.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1719_CR48","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/s41467-019-09407-3","volume":"10","author":"PA Nguyen","year":"2019","unstructured":"Nguyen PA, Born DA, Deaton AM, Nioi P, Ward LD. Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nat Commun. 2019;10:1579. https:\/\/doi.org\/10.1038\/s41467-019-09407-3.","journal-title":"Nat Commun"},{"issue":"2","key":"1719_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41573-022-00561-w","volume":"22","author":"KJ Carss","year":"2023","unstructured":"Carss KJ, Deaton AM, Del Rio-Espinola A, Diogo D, Fielden M, Kulkarni DA, et al. Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discov. 2023;22(2):145\u201362. https:\/\/doi.org\/10.1038\/s41573-022-00561-w.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1719_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1011638","volume":"21","author":"EV Minikel","year":"2025","unstructured":"Minikel EV, Nelson MR. Human genetic evidence enriched for side effects of approved drugs. PLoS Genet. 2025;21(3):e1011638. https:\/\/doi.org\/10.1371\/journal.pgen.1011638.","journal-title":"PLoS Genet"},{"key":"1719_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63762-y","volume":"16","author":"\u00c1 Duffy","year":"2025","unstructured":"Duffy \u00c1, Chen R, Stein D, Park JK, Mort M, Verbanck M, et al. Development of a genetic priority score to predict drug side effects using human genetic evidence. Nat Commun. 2025;16:8713. https:\/\/doi.org\/10.1038\/s41467-025-63762-y.","journal-title":"Nat Commun"},{"key":"1719_CR52","unstructured":"- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH guideline E8(R1) on general considerations for clinical studies [Internet]. Amsterdam: European Medicines Agency; 2021 [Internet, cited 2026 August 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf."},{"key":"1719_CR53","unstructured":"- Tydings C. CDER\u2019s clinical consideration for first-in-human trials [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024 Sep 4 [Internet, cited 2026 August 20]. Available from: https:\/\/www.fda.gov\/media\/184323\/download."},{"issue":"11","key":"1719_CR54","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.xphs.2023.07.005","volume":"112","author":"R Yadav","year":"2023","unstructured":"Yadav R, Sukumaran S, Lutman J, Mitra MS, Halpern W, Sun T, et al. Utilizing PK and PD biomarkers to guide the first-in-human starting dose selection of MTBT1466A: a novel humanized monoclonal anti-TGF\u03b23 antibody for the treatment of fibrotic diseases. J Pharm Sci. 2023;112(11):2910\u201320. https:\/\/doi.org\/10.1016\/j.xphs.2023.07.005.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1719_CR55","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/pds.4752","volume":"28","author":"CA Pinto","year":"2019","unstructured":"Pinto CA, Tervonen T, Marsh K, Lambrelli D, Schultze A, Tershakovec A, et al. Personalized benefit-risk assessments combining clinical trial and real-world data provide further insights into which patients may benefit most from therapy: demonstration for a new oral antiplatelet therapy. Pharmacoepidemiol Drug Saf. 2019;28(4):443\u201351. https:\/\/doi.org\/10.1002\/pds.4752.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1719_CR56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/9781119413431.ch7","volume-title":"Pharmacoepidemiology","author":"NM Gatto","year":"2019","unstructured":"Gatto NM, Sobel RE, Geier J, Mo J, Bate A, Reynolds RF. The role of pharmacoepidemiology in industry. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 6th ed. Hoboken: Wiley Blackwell; 2019. p. 98\u2013125.","edition":"6th ed"},{"issue":"6","key":"1719_CR57","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568\u201379. https:\/\/doi.org\/10.1056\/NEJMoa0706135. (PMID: 18256392).","journal-title":"N Engl J Med"},{"issue":"12","key":"1719_CR58","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1009717.","journal-title":"N Engl J Med"},{"key":"1719_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4848","volume":"351","author":"TM Ko","year":"2015","unstructured":"Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848. https:\/\/doi.org\/10.1136\/bmj.h4848.","journal-title":"BMJ"},{"issue":"6","key":"1719_CR60","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","volume":"155","author":"H Liu","year":"2019","unstructured":"Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155(6):666\u201372. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5360.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1719_CR61","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","volume":"144","author":"KC Konvinse","year":"2019","unstructured":"Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183\u201392. https:\/\/doi.org\/10.1016\/j.jaci.2019.01.045.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1719_CR62","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/all.16576","volume":"80","author":"C Mayorga","year":"2025","unstructured":"Mayorga C, Fernandez-Santamaria R, \u00c7elik GE, Labella M, Murdaca G, Sokolowska M, et al. Endotypes in immune mediated drug reactions: present and future of relevant biomarkers. An EAACI Task Force Report. Allergy. 2025;80(7):1831\u201347. https:\/\/doi.org\/10.1111\/all.16576.","journal-title":"Allergy"},{"issue":"4","key":"1719_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jjco\/hyad184","volume":"54","author":"Y Liang","year":"2024","unstructured":"Liang Y, Maeda O, Ando Y. Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Jpn J Clin Oncol. 2024;54(4):365\u201375. https:\/\/doi.org\/10.1093\/jjco\/hyad184.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1719_CR64","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cancers16061225","volume":"16","author":"B Ponvilawan","year":"2024","unstructured":"Ponvilawan B, Khan AW, Subramanian J, Bansal D. Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors. Cancers (Basel). 2024;16(6):1225. https:\/\/doi.org\/10.3390\/cancers16061225.","journal-title":"Cancers (Basel)."},{"key":"1719_CR65","unstructured":"U.S. Food and Drug Administration. Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products: guidance for industry. Silver Spring (MD): FDA; 2024 Jul. [Internet, cited 2026 August 20] Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory."},{"key":"1719_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024.1445998","volume":"4","author":"TA Hammad","year":"2024","unstructured":"Hammad TA, Davis S, Afsar S. Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence. Front Drug Saf Regul. 2024;4:1445998. https:\/\/doi.org\/10.3389\/fdsfr.2024.1445998.","journal-title":"Front Drug Saf Regul"},{"issue":"11","key":"1719_CR67","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","volume":"149","author":"M Salas","year":"1999","unstructured":"Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981\u20133. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a009758.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"1719_CR68","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/oxfordjournals.aje.a008895","volume":"144","author":"L Blais","year":"1996","unstructured":"Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta2-agonists. Am J Epidemiol. 1996;144(12):1161\u20139. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a008895.","journal-title":"Am J Epidemiol"},{"key":"1719_CR69","unstructured":"Occupational Safety and Health Administration. Using leading indicators to improve safety and health outcomes. Washington (DC): U.S. Department of Labor, Occupational Safety and Health Administration; 2019. OSHA publication no.: OSHA 3970. [Internet, cited 2026 August 20] Available from: https:\/\/www.osha.gov\/sites\/default\/files\/publications\/OSHA_LEADING_INDICATORS.pdf."},{"key":"1719_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-026-01683-5","author":"TA Hammad","year":"2026","unstructured":"Hammad TA, Rochon J. Analytic misjudgment of drug safety evidence and causality: from the Prosecutor\u2019s Fallacy and Simpson\u2019s Paradox to artificial intelligence. Drug Saf. 2026. https:\/\/doi.org\/10.1007\/s40264-026-01683-5.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01719-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01719-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01719-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:03:14Z","timestamp":1787936594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01719-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":71,"alternative-id":["1719"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01719-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TH and JR are employed by Takeda. KG is employed by AbbVie. AB is employed by GSK. Each of these authors owns stock in their respective employer. GT and AB are Editorial Board members of\n                      Drug Safety\n                      . GT and AB were not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. No other competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The article does not involve human subjects research, patient data, or clinical interventions.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article because no datasets were generated or analyzed for this paper. All information supporting the arguments in this article is contained within the paper and its references.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TH conceived the manuscript. All authors contributed to the writing, revision, and editing of the manuscript and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this publication are solely those of the authors and do not necessarily represent the views of, or imply endorsement by, their employer.","order":8,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}